BLU-808
Phase 2Small molecule
BLU-808 is one of 67 small molecule programs targeting Conjunctivitis. It is currently in Phase 2.
2
Indications
3
Total Trials
1
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
59 competitors in Chronic Spontaneous Urticaria
#DrugCompanyPhaseTrials
1Claritin
PPerrigo Company
Approved
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Xolair
RochePhase 2
Bilaxten
MMenarini International Operations Luxembourg SA
Phase 3
LOU064
NovartisPhase 3
Xolair
RochePhase 3
Opzelura
PfizerPhase 2
Barzolvolimab
CCelldex Therapeutics
Phase 3
Fasenra
AstraZenecaPhase 2
Tezspire
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BLU-808. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBlueprint Medicines